Cargando…
Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study
Human milk is considered the optimal nutrition for infants and found to contain significant numbers of viable bacteria. The aim of the study was to assess the effects of a specific synbiotic combination at doses closer to the bacterial cells present in human milk, on intestinal bifidobacteria propor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878856/ https://www.ncbi.nlm.nih.gov/pubmed/33574421 http://dx.doi.org/10.1038/s41598-021-83009-2 |
_version_ | 1783650408655224832 |
---|---|
author | Phavichitr, Nopaorn Wang, Shugui Chomto, Sirinuch Tantibhaedhyangkul, Ruangvith Kakourou, Alexia Intarakhao, Sukkrawan Jongpiputvanich, Sungkom Roeselers, Guus Knol, Jan |
author_facet | Phavichitr, Nopaorn Wang, Shugui Chomto, Sirinuch Tantibhaedhyangkul, Ruangvith Kakourou, Alexia Intarakhao, Sukkrawan Jongpiputvanich, Sungkom Roeselers, Guus Knol, Jan |
author_sort | Phavichitr, Nopaorn |
collection | PubMed |
description | Human milk is considered the optimal nutrition for infants and found to contain significant numbers of viable bacteria. The aim of the study was to assess the effects of a specific synbiotic combination at doses closer to the bacterial cells present in human milk, on intestinal bifidobacteria proportions (relative abundance), reduction of potential pathogens and gut physiological conditions. A clinical study was conducted in 290 healthy infants aged from 6 to 19 weeks. Infants received either a control infant formula or one of the two investigational infant formulas (control formula with 0.8 g/100 ml scGOS/lcFOS and Bifidobacterium breve M-16V at either 1 × 10(4) cfu/ml or 1 × 10(6) cfu/ml). Exclusively breastfed infants were included as a reference. Analyses were performed on intention-to-treat groups and all-subjects-treated groups. After 6 weeks of intervention, the synbiotics at two different doses significantly increased the bifidobacteria proportions in healthy infants. The synbiotic supplementation also decreased the prevalence (infants with detectable levels) and the abundance of C. difficile. Closer to the levels in the breastfed reference group, fecal pH was significantly lower while l-lactate concentrations and acetate proportions were significantly higher in the synbiotic groups. All formulas were well tolerated and all groups showed a comparable safety profile based on the number and severity of adverse events and growth. In healthy infants, supplementation of infant-type bifidobacterial strain B. breve M-16V, at a dose close to bacterial numbers found in human milk, with scGOS/lcFOS (9:1) created a gut environment closer to the breastfed reference group. This specific synbiotic mixture may also support gut microbiota resilience during early life. Clinical Trial Registration This clinical study named Color Synbiotics Study, was registered in ClinicalTrials.gov on 18 March 2013. Registration number is NCT01813175. https://clinicaltrials.gov/ct2/show/NCT01813175. |
format | Online Article Text |
id | pubmed-7878856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78788562021-02-12 Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study Phavichitr, Nopaorn Wang, Shugui Chomto, Sirinuch Tantibhaedhyangkul, Ruangvith Kakourou, Alexia Intarakhao, Sukkrawan Jongpiputvanich, Sungkom Roeselers, Guus Knol, Jan Sci Rep Article Human milk is considered the optimal nutrition for infants and found to contain significant numbers of viable bacteria. The aim of the study was to assess the effects of a specific synbiotic combination at doses closer to the bacterial cells present in human milk, on intestinal bifidobacteria proportions (relative abundance), reduction of potential pathogens and gut physiological conditions. A clinical study was conducted in 290 healthy infants aged from 6 to 19 weeks. Infants received either a control infant formula or one of the two investigational infant formulas (control formula with 0.8 g/100 ml scGOS/lcFOS and Bifidobacterium breve M-16V at either 1 × 10(4) cfu/ml or 1 × 10(6) cfu/ml). Exclusively breastfed infants were included as a reference. Analyses were performed on intention-to-treat groups and all-subjects-treated groups. After 6 weeks of intervention, the synbiotics at two different doses significantly increased the bifidobacteria proportions in healthy infants. The synbiotic supplementation also decreased the prevalence (infants with detectable levels) and the abundance of C. difficile. Closer to the levels in the breastfed reference group, fecal pH was significantly lower while l-lactate concentrations and acetate proportions were significantly higher in the synbiotic groups. All formulas were well tolerated and all groups showed a comparable safety profile based on the number and severity of adverse events and growth. In healthy infants, supplementation of infant-type bifidobacterial strain B. breve M-16V, at a dose close to bacterial numbers found in human milk, with scGOS/lcFOS (9:1) created a gut environment closer to the breastfed reference group. This specific synbiotic mixture may also support gut microbiota resilience during early life. Clinical Trial Registration This clinical study named Color Synbiotics Study, was registered in ClinicalTrials.gov on 18 March 2013. Registration number is NCT01813175. https://clinicaltrials.gov/ct2/show/NCT01813175. Nature Publishing Group UK 2021-02-11 /pmc/articles/PMC7878856/ /pubmed/33574421 http://dx.doi.org/10.1038/s41598-021-83009-2 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Phavichitr, Nopaorn Wang, Shugui Chomto, Sirinuch Tantibhaedhyangkul, Ruangvith Kakourou, Alexia Intarakhao, Sukkrawan Jongpiputvanich, Sungkom Roeselers, Guus Knol, Jan Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
title | Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
title_full | Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
title_fullStr | Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
title_full_unstemmed | Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
title_short | Impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
title_sort | impact of synbiotics on gut microbiota during early life: a randomized, double-blind study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878856/ https://www.ncbi.nlm.nih.gov/pubmed/33574421 http://dx.doi.org/10.1038/s41598-021-83009-2 |
work_keys_str_mv | AT phavichitrnopaorn impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT wangshugui impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT chomtosirinuch impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT tantibhaedhyangkulruangvith impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT kakouroualexia impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT intarakhaosukkrawan impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT jongpiputvanichsungkom impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT roeselersguus impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy AT knoljan impactofsynbioticsongutmicrobiotaduringearlylifearandomizeddoubleblindstudy |